SOURCE: Alexion PharmaceuticalsDESCRIPTION:
In the six-plus years I’ve been at Alexion, I’ve seen many changes. One constant, though, has been our commitment to solutions informed by not only patients’ physical conditions, but also their social and emotional needs.
In 2019, we launched Solutions To Accelerate Results (STAR) for patients to ensure we develop deep expertise in understanding patient insights and accelerate patient-centered innovation. The STAR team has taken this commitment to a new level. Patient insights and innovative solutions garnered through STAR are informing research and early clinical trial development, helping to better anticipate patient challenges.
In 2020, we more fully integrated our proprietary Patient and Stakeholder Value (PSv) Framework into the Alexion Product to Patient (AP2P) operating model to ensure we are identifying and embedding into the Alexion drug development teams those patient insights that will create the greatest value.
Every year, we conduct STAR PSv disease workshops. These are forums where we invite patients and other stakeholders to share with us their insights about living with a rare disease. In 2020, we conducted two STAR PSv workshops (ALS and dermatomyositis), both virtually, with participation from patients, caregivers and physicians. One of the workshops uncovered a need for mental health resources across our portfolio, which inspired our teams to co-create solutions to provide mental health support to patients and caregivers living with rare diseases. The Alexion team is now evaluating an online tool to help meet this need.
Actively listening to patients and all our stakeholders to uncover how we might best meet their needs and expectations is what inspires me and what gets me up in the morning, every single workday. This is delivering on our employee and patient experience.
Head of STAR Strategy and Planning
This is an excerpt from Alexion’s 2020 CSR Report. To read more, please visit csr.alexion.com
KEYWORDS: NASDAQ::ALXN, Alexion